Document Detail

Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study.
MedLine Citation:
PMID:  19202157     Owner:  NLM     Status:  MEDLINE    
AIMS: To evaluate the effect of atorvastatin in achieving stable sinus rhythm (SR) 30 days after electrical cardioversion (CV) in patients with persistent atrial fibrillation (AF). METHODS AND RESULTS: The study included 234 patients. The patients were randomized to treatment with atorvastatin 80 mg daily (n = 118) or placebo (n = 116) in a prospective, double-blinded fashion. Treatment was initiated 14 days before CV and was continued 30 days after CV. The two groups were well-balanced with respect to baseline characteristics. Mean age was 65 +/- 10 years, 76% of the patients were male and 4% had ischaemic heart disease. Study medication was well-tolerated in all patients but one. Before primary endpoint 12 patients were excluded. In the atorvastatin group 99 patients (89%) converted to SR at electrical CV compared with 95 (86%) in the placebo group (P = 0.42). An intention-to-treat analysis with the available data, by randomization group, showed that 57 (51%) in the atorvastatin group and 47 (42%) in the placebo group were in SR 30 days after CV (OR 1.44, 95%CI 0.85-2.44, P = 0.18). CONCLUSION: Atorvastatin was not statistically superior to placebo with regards to maintaining SR 30 days after CV in patients with persistent AF.
Henrik Almroth; Niklas Höglund; Kurt Boman; Anders Englund; Steen Jensen; Björn Kjellman; Per Tornvall; Mårten Rosenqvist
Related Documents :
16946597 - Outcome of patients in relation to duration of new-onset atrial fibrillation following ...
17161267 - A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic dru...
16489647 - Atrial fibrillation after surgery for esophageal carcinoma: clinical and prognostic sig...
18381187 - Management of atrial fibrillation in patients with heart failure.
17919617 - Prognostic value of brain natriuretic peptide in heart transplant patients.
12913937 - Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome ...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-02-06
Journal Detail:
Title:  European heart journal     Volume:  30     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-02     Completed Date:  2009-06-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  827-33     Citation Subset:  IM    
Department of Cardiology, Orebro University Hospital, Orebro, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / adverse effects,  therapeutic use*
Atrial Fibrillation / drug therapy*
Double-Blind Method
Electric Countershock*
Heptanoic Acids / adverse effects,  therapeutic use*
Prospective Studies
Pyrroles / adverse effects,  therapeutic use*
Recurrence / prevention & control
Treatment Outcome
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pressure-volume loop analysis during implantation of biventricular pacemaker/cardiac resynchronizati...
Next Document:  A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and with...